Navigation Links
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors

SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L. Newman , M.D., to the company's board of directors.

"We are very pleased to welcome Dr. Newman to our board of directors. His experience in the evolving sector of integrated delivery networks, significant healthcare operations experience, and clinical background will be an invaluable addition to our board as we seek to expand our portfolio of products for use within the hospital setting," stated Cam Garner , Chairman of Cadence.

Dr. Newman served in positions of increasing responsibility with Tenet Healthcare Corporation (NYSE: THC), including as Vice Chairman from January 2012 until his retirement in June 2012. Since joining Tenet in 1999, he also served as Corporate Chief Operating Officer and Executive Vice President of Tenet Healthcare Corporation, Chief Executive Officer of Tenet HealthSystem, California, and as Senior Vice President, Gulf States Region, of Tenet HealthSystem. Prior to joining Tenet, Dr. Newman held executive positions at Columbia/HCA, Inc., and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans. Earlier in his career, Dr. Newman was an Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine, and Director of Gastroenterology and Nutrition Support at Children's Medical Center in Dayton, Ohio.  Dr. Newman is currently a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and a member of the Board of Directors of Optimer Pharmaceuticals, Inc. and Hansen Medical, Inc.  He holds a bachelor's degree from Rutgers University, an M.B.A. from Tulane University and a medical degree from the University of Tennessee. Dr. Newman completed his internship, residency and fellowship at Emory University School of Medicine, and has also completed the Advanced Management Program at the University of Pennsylvania's Wharton School of Business.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of under "Events & Presentations" by selecting "Corporate Overview."

CADENCE® and OFIRMEV® are registered trademarks of Cadence Pharmaceuticals, Inc.


William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
5. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
6. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
7. Cadence Pharmaceuticals to Host Analyst and Investor Day
8. Cadence to Open Finished Medical Device Facility
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
10. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
Post Your Comments:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):